君圣泰医药-B(02511)任命Filip Surmont博士为首席医学官 强化心肾代谢系统疾病(CKM)布局

Group 1 - The core point of the article is the appointment of Dr. Filip Surmont as Chief Medical Officer of Junsheng Tai Pharmaceutical-B (02511), who will oversee the company's medical strategy, clinical development, and related medical affairs [1] - The appointment aims to enhance the research and development progress and value of the company's core pipeline in the field of cardio-renal metabolic diseases (CKM) [1]